Medical Pharmcology: Parkinson's Disease Practice Questions

Medical Pharmacology Chapter 18: Antiparkinson's Disease Drug Practice Questions

Neurological and neuroanatomical aspects of Parkinsonism:
1. mainly a disease of the cerebellum
2. can be cured by a combination of L-DOPA and anticholinergic drugs
3. is associated with the basal ganglia which consists of neostriatum, globus pallidus
4. B & C
Neurological presentations of Parkinsonism EXCEPT:
1. rigidity
2. hyperkinesia
3. tremor
4. postural disturbances.
ANS (autonomic nervous system) manifestations in Parkinson's disease:
1. tremor
2. rigidity
3. micrographia
4. sialorrhea
Anticholinergic drug(s) used in Parkinsonism:
1. benztropine
2. cycrimine
3. amantadine
4. A & B
Primary drug used in managing Parkinson's disease
1. amantadine
2. L-DOPA
3. selegiline
4. pergolide
Factors that argue against initial use of benztropine in a patient with mild Parkinson's disease:
1. old age
2. prostatic hypertrophy
3. narrow angle glaucoma
4. all of the above
Pharmacological characteristics of L-DOPA
1. not itself pharmacologically active
2. cannot cross the blood-brain barrier
3. can be curative if initiated early enough.
4. metabolized only in the brain--due to the presence of a unique dopa-decarboxylase
Anti-Parkinson Drug that probably acts by direct dopamine receptor simulation.
1. benztropine
2. selegiline
3. bromocriptine
4. amantadine
Bromocriptine side effect(s)
1. mental changes
2. postural hypotension
3. dyskinesias
4. A, B, & C
Pharmacological management of malignant neuroleptic syndrome:
1. dantrolene
2. bromocriptine
3. amantadine
4. A, B, & C